PLATFORM (2)
Radiation Protection

These products are under active development in-house and in collaboration with the US Radiation Countermeasures Armed Forces Radiobiology Research Institute (AFRRI) as per our strategic development plan 2007-2009.

(2)(a) Acute Radiation Syndrome (ARS) Therapy - Non-steroidal oral therapeutic molecules (CB700 & CB1400).
The two molecules which Canopus BioPharma has under current development for the treatment of ARS are coded CB700 and CB1400.

CB700 is a cytokinin, type molecule. It was developed in the 1970's by Roswell Memorial Institute, Buffalo, New York, USA, as an anti-cancer agent and has completed its animal toxicity and IND phase II human studies at Roswell. A Drug Master File (DMF) for the bulk production of the CB700 is in existence.

CB1400 is a synthetic member of the dithiolethiones family of molecules. Ongoing research by Canopus BioPharma has demonstrated that these molecules enhance the DNA repair enzyme levels which are essential for the repair and recovery of cellular DNA which has been damaged by radiation.

Post-radiation exposure study:
In order to validate and independently confirm efficacy of our ARS combination therapeutic approach Canopus BioPharma commissioned the following studies. Under contract a study of the protection of mice liver and haematopoietic colony forming cells (GM-CFC) from irradiation injury by compounds CB700(A) and CB1400(B) alone and in combination was commissioned. The report of the study shows a significant enhancement of GM-CFC by the compounds, additional dose level studies are planned to optimize the dose.

Pre-radiation exposure study:
Study 1. Canopus BioPharma undertook a study, at an independent research facility in India, in a radiation pre-treatment animal model, using CB700. In our experiments CB700 completely protected the irradiated mice against GI death at 150 mg of CB700 administered orally. This is first time in radiation research history that laboratory animals have been completely protected from GI damage at a dose of 10Gy. These observations were confirmed by repetition of the experiment.

Study 2. Canopus BioPharma, at a second independent radiation research center, completed a study on the Antimutagenic and Radioprotective effects of our compound CB1400.

Radiation Protection Summary
Canopus BioPharma reached a pivotal milestone with the development of its Radiation Protection drug candidates when the US Radiation Countermeasures Armed Forces Radiobiology Research Institute (AFRRI) Bethesda, MD USA agreed to undertake further development and testing in October 2006. This important research work is currently ongoing.